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This study aims to examine the relationship between BMI and clinical outcomes following percutaneous coronary intervention (PCI) and to determine the relevance of different clinical presentations requiring PCI on this relationship. 
Background
Obesity is a growing problem and studies have reported a protective effect from obesity compared to normal BMI for adverse outcomes after PCI.
Methods
Between 2005 to 2013, 345,192 participants were included.  Data were obtained from the British Cardiovascular Interventional Society (BCIS) registry and mortality were obtained through the UK Office of National Statistics.  Multiple logistic regression was performed to determine the association between body mass index (BMI) group (<18.5, 18.5-24.9, 25-30 and >30 kg/m2) and adverse in-hospital outcomes and mortality.  
Results
At 30 days post-PCI, significantly lower mortality was seen in patients with elevated BMI (OR 0.86 95%CI 0.80-0.93 and OR 0.90 95%CI 0.82-0.98 for BMI 25-30 and BMI >30, respectively). At 1-year post-PCI, and up to 5 years post-PCI, elevated BMI (either overweight or obese) was an independent predictor of greater survival compared to normal weight (OR 0.70 95%CI 0.67-0.73 and OR 0.73  95%CI 0.69-0.77 respectively for 1 year and OR 0.78 95%CI 0.75-0.81 and OR 0.88 95%CI 0.84-0.92, respectively for 5 years.  Similar reductions in mortality were observed for the analysis according to clinical presentations (Stable angina, unstable angina/NSTEMI and STEMI).
Conclusions
A paradox regarding the independent association of elevated BMI to reduced mortality after PCI is still evident in contemporary UK practice. This is seen in both stable and more acute clinical settings. 
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Obesity is a growing worldwide health concern. In the United States, recent data indicate that more than one third of adults, and around one in five children or adolescents, are obese (1,2). The estimated cost of obesity in the US was $147 billion in 2008, based on Center of Disease Control and Prevention data (3). Obesity predicts coronary artery disease and premature death (4,5), and it is estimated that obese non-smokers lose up to 7 years of life expectancy compared to normal weight non-smokers (6).
	Notwithstanding these statistics, multiple studies have demonstrated an apparently protective effect from obesity, compared to a 'normal' BMI, when considering in-hospital and even longer-term clinical endpoints (7). This so-called 'obesity paradox' has been noted in various settings but was first described in the context of PCI outcomes by Ellis et al (8), who noted a decreased risk of in-hospital mortality associated with a BMI of 26-34 compared to levels greater or lower than this. Subsequent work by Gruberg and colleagues (9), looking at over 9000 consecutive PCIs between 1994 and 1999 observed that obese patients (BMI>30) were, on average, younger and had a higher incidence of cardiac risk factors, including hypertension, diabetes, high cholesterol and smoking. There was no difference in PCI acute procedural success between BMI groups in their study. However, obese patients had fewer complications and lower in-hospital and 1-year mortality, and BMI was an independent predictor of favorable clinical outcomes. Several other published studies have supported this association (10-13) including a meta-analysis combining outcomes at 1-5 years from 5 separate studies (12). However, there have been some conflicting results from other work (14-16) that has not identified this survival paradox.
	The largest single study in this field retrospectively analysed 50,149 STEMI patients from the US National Cardiovascular Data Registry (NCDR) (17). It demonstrated a 'U-shaped' curve relationship between obesity and outcome in unadjusted analyses, with an 'obesity paradox' benefit for overweight and obese patients but a detrimental outcome in the extreme, class III obese (BMI>40). However, when confounding variables were taken into account, the obesity paradox (obese vs. normal BMI) for in-hospital mortality was eliminated, although there remained an increased propensity for major bleeding in both normal weight patients and class III obese BMI, compared to class 1 obese (BMI 30-35) (17). Elsewhere, there are very limited data on whether the relationship of PCI outcome to obesity is similar across the different indications for PCI (i.e. STEMI, NSTEMI and stable angina) (18) and here again, discordant findings have resulted in uncertainty. 
	We analysed contemporary UK PCI data from anunselected national cohort, derived from the British Cardiovascular Interventional Society (BCIS) database, between 2005 and 2013. Our aim was to explore the ‘obesity paradox’ following PCI. We also analysed differences in the relationship of obesity to outcomes based on the clinical indication for PCI. 

Methods
We analyzed PCI data collected on behalf of the British Cardiovascular Intervention Society (BCIS) by the National Institute of Cardiovascular Outcomes Research (NICOR).  This dataset records PCI procedures performed in all UK hospitals.  In 2012, the database contained 99.4% of all PCI procedures performed in the National Health Service (NHS) hospitals in England and Wales (web reference www.bcis.org.uk).
The BCIS-NICOR database records clinical, procedural and outcome information with a total of 113 variables. Mortality was tracked using each patients' unique National Health Service (NHS) numbers, by linkage with records held by the Office of National Statistics.  This process is only available for patients resident in England and Wales, who represent the large majority of UK population, and so patients living in Scotland and Northern Ireland were not included in this study (19-21).
We therefore analyzed all patients who underwent PCI in England and Wales between 1 January 2005 to 31 December 2013 with values for body mass index (BMI) and mortality outcomes at 30-days and 1 year. Patients were classified according to BMI groups: BMI <18.5 kg/m2, BMI 18.5-24.9 kg/m2, BMI 25.0-30.0 kg/m2 and BMI >30 kg/m2. The outcomes were 30-day mortality, 1-year mortality, major adverse cardiovascular events (MACE) and major bleeding. MACE was defined as the composite of in-hospital re-infarction, re-PCI, emergency CABG and in hospital mortality.
Statistical analysis




Between 2005 to 2013, there were 345,192 records in the BCIS database with data for BMI for patients who underwent PCI procedures.  The extent of available and missing data is shown in Supplementary Table 1.  
The proportion of patients undergoing PCI who were obese from 2005 to 2013.
The percentage of participants undergoing PCI with a BMI >30kg/m2 showed a small but significant increase (p=0.002) from 30% in 2005 to 32% in 2013 (Figure 1). 
Baseline clinical characteristics, periprocedural factors and unadjusted outcomes.
Table 1 presents baseline characteristics, divided by BMI into four groups as defined by the WHO: lean BMI <18.5kg/m2, normal BMI 18.5-24.9 kg/m2, overweight BMI 25-30 kg/m2 and obese BMI >30 kg/m2. We compared characteristics in each group. Obese patients weresignificantly younger (p<0.001) compared to other groups. Obese patients, when compared to those with a normal BMI, were more often smokers (66% c.f. 63%, p<0.001) and had features of the metabolic syndrome associated with obesity, namely hypertension (62% c.f. 49%, p<0.001), hypercholesterolemia (61% c.f. 53%, p<0.001) and diabetes (29% c.f. 13%, p<0.001). Left ventricular ejection fraction was somewhat more likely to be good in obese patients (76% had good LV function c.f. 72% of normal BMI patients). Radial access was slightly more commonly used in obese patients (48% c.f. 44% in normal BMI, p<0.001) but there was no significant difference in the proportion receiving drug eluting stents.A much larger proportion of PCI for STEMI was performed in lean, compared to obese patients (24% c versus. 12%, p<0.001). Conversely, a greater proportion of PCIs in obese patients were performed for stable angina compared to lean BMI patients (52% c.f. 30%, p<0.001).
Lean patients (BMI <18.5 kg/m2) were significantly older, less likely to be male (46% c.f. 71%), tended to have a poorer left ventricular function (67% had good LV c.f. 72%), less radial access use (41% c.f. 44%) and less frequent treatment with drug eluting stents (66% c.f. 69%) compared to normal BMI patients.
Unadjusted crude mortality suggested the presence of an obesity paradox with better survival in obese patients, and this relationship was more evident at longer follow up time frames. Crude 30-day mortality was 1% in the obese, compared to 2% in patients with normal BMI and 4% in the lean (p<0.001). At one year, mortality in the obese was 3%, compared to 6% in patients with normal BMI and 14% in the lean (p<0.001). At 5 years, crude mortality is 19% in the obese, 28% in normal BMI and 53% in the lean (p<0.001). 

Statistical analysis of adverse outcome according to BMI group.
Statistical multivariable analysis of outcome data at between 30 days and 5 years post-PCI is presented in Table 2. At 30 days, the unadjusted odds ratio in the obese group was 0.49, compared to 1 in normal BMI and 1.68 in lean patients (p<0.001). After adjusting for the factors above, the odds of 30-day mortality remained significantly decreased in both the BMI 25-30 (OR 0.86;95% CI 0.80-0.93, P=0.001) and BMI>30 (OR 0.90; 95% CI 0.82-0.98, P=0.016) groups but did not reach statistical significance in the BMI <18.5 group (OR 1.23;95% CI 0.98-1.54, P=0.077) (Figure 2). Similar observations were recorded at 1–year with independent decreases in the odds of mortality in the BMI 25-30 (OR 0.70;95% CI 0.67-0.73, P<0.001) and BMI >30 (OR 0.73; 95% CI 0.69-0.77, P<0.001) groups, and independent increases in odds of mortality for the BMI <18.5 group (OR 1.85; 95% CI 1.63-2.10, P<0.001). Similar trends were recorded at 3 years and 5 years.
Although in-hospital major adverse cardiac events (MACE) were more likely in the unadjusted data with rising BMI (odds ratio of 0.68 c.f. 1 in normal BMI and 1.24 in lean patients), after adjustments for differences in baseline covariates, the effect of BMI on MACE events was no longer significant.  Nevertheless the odds for in-hospital bleeding complications were significantly less in obese patients following multivariate analysis compared to normal BMI and lean patients (0.87 c.f. 1 c.f. 1.24, p<0.001).
Adjusted odds of adverse outcome in obese patients depending on clinical syndrome.
We then divided the recorded PCI data based on clinical presentation, i.e. stable angina, unstable angina / non-ST elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI), to examine the differential effect of BMI according to PCI indication (Table 3). Multivariable regression analysis yielded similar results to the overall PCI data. Unadjusted 30-day mortality was lower with higher BMI in stable angina, UA/NSTEMI and STEMI but this effect was no longer significant after statistical adjustment in the STEMI group. However, at 1 year, 3 years and 5 years, the adjusted odds of mortality in patients with obesity was significantly less than in patients with normal BMI in PCIs for stable angina, UA/NSTEMI and STEMI. Similarly, in lean patients (BMI<18.5) taking into account comorbidity, the adjusted odds for mortality were significantly increased at 1, 3 and 5 years. There were significantly fewer in hospital bleeds in obese patients compared to normal and lean patients in all three clinical syndromes, an effect that remained significant even after statistical adjustment. 
Inverse probability weighting by propensity scores analysis of adverse outcomes and BMI.
Inverse probability weighting (by propensity scores) analysis of adverse outcomes directly comparing different BMI groups is shown in Table 4. Using this method of analysis, both overweight and obese groups are seen to have a significantly lower odds of mortality than the normal BMI group at all studied time points (30 days out to 5 years), whilst the lean group had an increased odds of mortality at 1 year, 3 years and 5 years.  
Sensitivity analysis considering patients with BMI ≥30 kg/m2 compared to those with normal BMI
	Supplementary Table 2 shows the risk of adverse outcomes among participants with BMI ≥30 kg/m2 by BMI group.  Unadjusted estimates suggest that participants in all elevated BMI groups have lower odds mortality, MACE and bleeding compared to normal BMI controls.  However, after adjustment it appears that participants with BMI ≥40 kg/m2 have no significant difference in the odds of in-hospital MACE, in-hospital major bleeding or5-year mortality.
	Additional analysis considering the subgroup of participants admitted before or in the year 2009, after 2009 and those with and without diabetes showed similar trends as overall results (Supplementary Table 3-6).
Discussion
Our data shows significant differences in short, medium and long-term mortality independently associated with baseline BMI group – greater survival being seen in patients classified as overweight (BMI 25-30) or obese (BMI>30), as opposed to having normal BMI (BMI 18.5-24.9) at the time of PCI.In patients with BMI<18.5, worse clinical outcomes were observed both in the short and longer term. This significant effect persisted (albeit with reduced magnitude) even after adjustment for multiple potential confounding factors, as described. Furthermore, there was overall consistency between the findings from our main analysis, using multivariable logistic regression, and the alternate methodology using inverse probability weighting by propensity scores. The very large patient numbers involved also allowed us to undertake a meaningful subgroup analysis based on clinical presentation - here too a consistent pattern of findings was seen with better outcomes observed in overweight patients and worse outcomes recorded in those with a BMI<18.5, even after adjustment for differences in baseline covariates. 
Our study findings are consistent with results from threetwo recent systematic reviews and meta-analyses of the published literature for outcomes based on BMI after coronary revascularisation (22,23). Those studies involved 91,582 patients (in whom detailed medication use data were available) and 242,377 patients respectively, and hence each was significantly smaller than our cohort, in whom 30 day post-PCI mortality data were available in over 350,000 patients. The findings also are consistent with those of a recent meta-analysis of over 1.3 million patients that re-examined the link between mortality and BMI in coronary artery disease patients (not restricted solely to a PCI or revascularisation setting) (24). This too found short and long term mortality advantages for overweight or obese groups compared to normal BMI patients. Sharma et al conducted a systematic review and meta-analysis of the relationship between BMI and mortality, cardiovascular mortality and myocardial infarction after revascularization.[Sharma et al]  There review of 36 coronary artery bypass graft and PCI studies found that patients of low BMI had the highest risk of adverse events while those with high BMI had the fewest events.  Our current study provides further evidence that supports their findings.
	 The confirmation of a BMI paradox (for overweight and obese patients) in this large contemporary PCI population raises questions about potential unrecognized confounders, for which adjustment has not been made in our analysis. This is a feature common to all registry-based studies. For our BCIS cohort, 43 specific aspects are recognized as limitations. First, there is only limited recording of other (non-cardiac) comorbidities, which are pertinent to mortality at all-time points post-PCI (25,26). Second, we do not have access to accurate recording of guideline-recommended medical therapy use for these patients. Differences in their use would potentially impact on clinical outcomes and recent published work confirms that this may explain some, although seemingly not all, of the observed obesity paradox23. Third, measures of frailty or comorbidity (25,26) were not recorded in this dataset and may represent unmeasured confounders, and therefore contribute to the poorer outcomes reported in the low BMI group.  This is of particular importance in this analysis because weight loss may, be a manifestation of underlying ill health for a wide variety of reasons including heart failure or malignancy which in its most marked form, may present as cachexia. Inclusion of such patients in the ‘low BMI’ group will contribute to a higher rate of adverse clinical outcomes compared to those with greater BMI.Third,  measures of frailty or comorbidity (25,26) were not recorded in this dataset and may represent unmeasured confounders.  This is of particular importance in this analysis because weight loss may, be a manifestation of  underlying ill health for a wide variety of reasons including heart failure or malignancy whichin its most marked form, may present as cachexia. Inclusion of such patients in the ‘low BMI’ group will contribute to a higher rate of adverse clinical outcomes compared to those with greater BMI.  By extension, some of those in the ‘normal weight’ group may likewise have experienced prior weight loss due to comorbidity. However, the very large patient numbers involved in our study should ameliorate the impact from such an influence, since ‘hitherto healthy’ normal weight patients are likely to account for the majority of patients in this BMI grouping. Finally, the BCIS dataset does not capture data on post discharge secondary prevention therapies prescribed and differences in the provision of secondary care prevention amongst patients of different BMI may contribute to the outcomes reported.
A separate, more relevant issue however, is the acknowledged limitation of BMI as a measure of obesity. Important additive prognostic information comes from knowledge of fat distribution, with a recognized detrimental impact from ‘central obesity (27). Relevant data, such as waist circumference, are not available in the BCIS dataset. Hence, it is not possible to identify those who would fall into the category of ‘normal weight central obesity’ in order to refine our group classification system beyond BMI alone. Whether this would change our key findings is currently unknown.  Indeed, in a previous analysis of over 15,000 patients derived from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort that were prospectively followed up, waist to hip ratio was the strongest predictor of incident cardiovascular disease and mortality compared to either BMI or body fat percentage.[Myint PK, et al. Heart 2014;100:1613-9.]A separate, more relevant issue however, is the acknowledged limitation of BMI as ameasure of obesity. Important additive prognostic information comes from knowledge of fat distribution, with a recognized detrimental impact from ‘central obesity (27). Relevant data, such as waist circumference, are not available in the BCIS dataset. Hence, it is not possible to identify those who would fall into the category of ‘normal weight central obesity’ in order to refine our group classification system beyond BMI alone. Whether this would change our key findings is currently unknown. 
	In considering other explanations for our key study findings on mortality, we note that in-hospital major bleeding complications were lower in overweight and obese patients, and with bleeding independently associated with worse short and longer term mortality outcomes (28,29). A reduction in bleeding is likely driven to some extent by higher rates of radial access in patients with greater BMI. However other potential mechanisms for bleeding differences between BMI groups include appropriate dosing of peri-PCI anticoagulant therapy and differences in sheath-to-artery ratios (30). Indeed, dosing of anti-coagulation may be particularly relevant in acute settings such as STEMI where opportunities to gain an accurate measure of a patients weight may be limited, resulting in overdosing of patients with low BMI, whose weight might be over-estimated.However other potential mechanisms for bleeding differences between BMI groups include appropriate dosing of peri-PCI anticoagulant therapy and differences in sheath-to-artery ratios (30).
Finally, when trying to interpret our findings, consideration should be given to evidence of potentially protective effects from adipose tissue itself in various post-operative and post-procedural settings. Adipose tissue is important in the production of various hormones and cytokines including tissue necrosis factor, adiponectin and leptin (31). Whether these factors or others may be involved in the protective mechanisms against PCI-related complications is unclear (32).  Some experimental models indicate a protective effect of obesity against ischemia-reperfusion injury: for example, a hyperphagia-induced obese rat model has been shown to have smaller infarcts and improved functional recovery following reperfusion, with increased signalling shown in the reperfusion injury salvage kinase pathway (RISK) (33). Obesity-inducing diets in rats (sucrose-supplemented or a high fat diet) have also been shown to be cardioprotective (34). Harvested hearts were less susceptible to ischemia-reperfusion injury and had smaller infarct sizes, an effect not due to RISK signalling. Whilst a role for such pathways in influencing clinical outcomes is plausible in acute presentations (particularly ST elevation myocardial infarction) their relevance to PCI in stable settings is questionable. Nevertheless, our confirmation of earlier studies demonstrating a “BMI paradox” should provide support for mechanistic studies to explore this observation.
In this largest study to date examining the relationship between BMI and PCI outcomes, an obesity paradox is still evident in contemporary PCI. This paradox is encountered with PCI in both stable coronary disease and in more acute clinical situations. Factors underlying this phenomenon remain uncertain and controversial and this study provides support for further exploration. 
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Table 1: Descriptive statistics
Variable	BMI <18.5kg/m2 (n=3,007)	BMI 18.5-24.9 kg/m2(n=87,279)	BMI 25-30 kg/m2 (n=146,517)	BMI >30 kg/m2 (n=108,190)	p-value
Age	69.6 (±12.7)	67.1 (±12.0)	64.8 (±11.3)	62.4 (±10.9)	<0.001
Male gender	1,368/2,996 (46%)	61,398/86,873 (71%)	114,697/145,786 (79%)	77,805/107,677 (72%)	<0.001
CountryEnglandWales	2845 (95%)163 (5%)	82,431 (94%)4,889 (6%)	137,586 (94%)9,005 (6%)	100,983 (93%)7,250 (7%)	<0.001
Year200520062007200820092010201120122013	155 (5%)214 (7%)243 (8%)321 (11%)379 (13%)388 (13%)447 (15%)389 (13%)472 (16%)	5,217 (6%)7,724 (9%)8,936 (10%)9,605 (11%)10,318 (12%)10,854 (12%)11,114 (13%)11,142 (13%)12,410 (14%)	9,399 (6%)12,359 (8%)14,615 (10%)16,615 (11%)17,588 (12%)18,779 (13%)18,459 (13%)18,867 (13%)19,910 (14%)	6,374 (6%)8641 (8%)10,553 (10%)12,361 (11%)12,910 (12%)13,902 (13%)13,904 (13%)14,075 (13%)15,513 (14%)	<0.001
RaceCaucasianBlackAsian/OrientalOther	2,015 (86%)18 (1%)157 (7%)153 (7%)	58,708 (85%)516 (1%)5,323 (8%)4,346 (6%)	99,096 (86%)817 (1%)7,507 (7%)7,492 (7%)	73,923 (88%)640 (1%)4,220 (5%)5,416 (6%)	<0.001
Smoker (current/ex)	1,839/2,741 (67%)	50,039/79,364 (63%)	86,814/135,039 (64%)	66,519/100,039 (66%)	<0.001
Family history of CAD	1,012/2,644 (38%)	35,229/77,784 (45%)	65,314/131,334 (50%)	51,725/97,069 (53%)	<0.001
Hypertension	1,364/2,898 (47%)	41,509/84,480 (49%)	76,475/142,171 (54%)	64,889/105,166 (62%)	<0.001
Hypercholesterolemia	1,360/2,898 (47%)	44,900/84,480 (53%)	81,500/142,171 (57%)	64,019/105,166 (61%)	<0.001
Diabetes	284/2,867 (10%)	10,666/84,134 (13%)	23,980/141,347 (17%)	30,022/104,274 (29%)	<0.001
Peripheral vascular disease	214/2,898 (7%)	4,434/84,480 (5%)	6,151/142,171 (5%)	5,071/105,166 (5%)	<0.001
Previous MI	851/2,874 (30%)	23,609/83,192 (28%)	41,224/139,505 (30%)	32,135/103,004 (31%)	<0.001
Previous stroke	137/2,898 (5%)	3,499/84,480 (4%)	5,296/142,171 (4%)	4,095/105,166 (4%)	<0.001
Valvular heart disease	81/2,898 (3%)	1,262 /84,480 (1%)	1,689/142,171 (1%)	1,130/105,166 (1%)	<0.001
Renal disease	97/2,984 (3%)	2,310/86,634 (3%)	3,222/145,421 (2%)	2,686/107,407 (3%)	<0.001
Previous PCI	515/2,925 (18%)	17,927/85,288 (21%)	33,700/143,319 (24%)	26,896/105,874 (25%)	<0.001
Previous CABG	162/2,929 (6%)	6,706/85,349 (8%)	13,374/143,089 (9%)	9,943/105,726 (9%)	<0.001
LV ejection fractionGoodModeratePoor	954 (67%)346 (24%)123 (9%)	30,713 (72%)9,473 (22%)2,642 (6%)	54,742 (76%)14,139 (20%)3,295 (5%)	41,160 (76%)10,665 (20%)2,349 (4%)	<0.001
Receipt of ventilation	28/2,766 (1%)	1,005/80,035 (1%)	1,418/133,418 (1%)	822/98,309 (1%)	<0.001
Receipt of circulatory support	79/2,837 (3%)	1,946/82,603 (2%)	2,182/137,987 (2%)	1,255/101,765 (1%)	<0.001
Cardiogenic shock	74/2,872 (3%)	1,791/83,017 (2%)	2,035/138,543 (1%)	1,148/102,193 (1%)	<0.001
Left main 	127/2,895 (4%)	3,176/84,464 (4%)	4,647/141,314 (3%)	3,346/104,367 (3%)	<0.001
Use of drug eluting stents	56,140/84,621 (66%)	97,649/141,722 (69%)	71,530/104,477 (68%)	1,660/2,909 (57%)	<0.001
Radial access	1,208/2,942 (41%)	38,007/85,438 (44%)	65,562/143,257 (46%)	51,228/105,646 (48%)	<0.001
Glycoprotein IIb/IIIa inhibitor	597/2,823 (21%)	19,756/82,240 (24%)	33,021/137,244 (24%)	22,698/101,206 (22%)	<0.001
DiagnosisStable anginaUA/NSTEMISTEMI	842 (30%)1,330 (47%)678 (24%)	33,295 (40%)33,683 (41%)15,528 (19%)	66,808 (48%)51,575 (37%)20,172 (15%)	53,610 (52%)37,029 (36%)12,145 (12%)	<0.001
30 day mortality	103/2,945 (4%)	1,817/85,595 (2%)	1,858/143,741 (1%)	1,125/106,294 (1%)	<0.001
1 year mortality	373/2,754 (14%)	5,044/80,420 (6%)	4,792/135,485 (4%)	3,137/99,673 (3%)	<0.001
3 years mortality	669/2,130 (31%)	9,035/60,473 (15%)	9,628/100,536 (10%)	6,652/73,138 (9%)	<0.001
5 years mortality	833/1,577 (53%)	11,818/42,476 (28%)	13,311/67,957 (20%)	9,317/48,705 (19%)	<0.001
MACE	84/2,938 (3%)	1,993/85,057 (2%)	2,611/142,797 (2%)	1,696/105,602 (2%)	<0.001




Table 2: Crude and adjusted odds of adverse outcome according to BMI group using imputed data
Outcome/adjustment	BMI <18.5 kg/m2	BMI 18.5-24.9 kg/m2	BMI 25-30 kg/m2	BMI >30 kg/m2
Unadjusted 30 day mortality (n=345,152)Odds ratio (95% CI)p-value	1.68 (1.38-2.06)*<0.001	1.00 (ref)	0.61 (0.57-0.65)*<0.001	0.49 (0.46-0.53)*<0.001
Adjusted 30 day mortality (n=345,152)Odds ratio (95% CI)p-value	1.23 (0.98-1.54)0.077	1.00 (ref)	0.86 (0.80-0.93)*0.001	0.90 (0.82-0.98)0.016
Unadjusted 1 year mortality (n=318,332)Odds ratio (95% CI)p-value	2.34 (2.09-2.62)*<0.001	1.00 (ref)	0.55 (0.53-0.67)*<0.001	0.49 (0.46-0.51)*<0.001
Adjusted 1 year mortality (n=318,332)Odds ratio (95% CI)p-value	1.85 (1.63-2.10)*<0.001	1.00 (ref)	0.70 (0.67-0.73)*<0.001	0.73 (0.69-0.77)*<0.001
Unadjusted 3 year mortality (n=230,639)Odds ratio (95% CI)p-value	2.58 (2.32-2.86)*<0.001	1.00 (ref)	0.61 (0.59-0.64)*<0.001	0.58 (0.56-0.61)*<0.001
Adjusted 3 year mortality (n=230,639)Odds ratio (95% CI)p-value	2.18 (1.93-2.45)*<0.001	1.00 (ref)	0.75 (0.72-0.78)*<0.001	0.82 (0.78-0.85)*<0.001
Unadjusted 5 year mortality (n=145,958)Odds ratio (95% CI)p-value	2.70 (2.39-3.05)*<0.001	1.00 (ref)	0.66 (0.64-0.69)*<0.001	0.65 (0.63-0.68)*<0.001
Adjusted 5 year mortality(n=145,958)Odds ratio (95% CI)p-value	2.48 (2.16-2.85)*<0.001	1.00 (ref)	0.78 (0.75-0.81)*<0.001	0.88 (0.84-0.92)*<0.001
Unadjusted MACE (n=345,152)Odds ratio (95% CI)p-value	1.24 (1.00-1.55)0.054	1.00 (ref)	0.78 (0.73-0.83)*<0.001	0.68 (0.64-0.72)*<0.001
Adjusted MACE (n=345,152)Odds ratio (95% CI)p-value	1.02 (0.81-1.29)0.85	1.00 (ref)	0.96 (0.90-1.02)0.21	0.95 (0.89-1.02)0.17
Unadjusted bleed (n=345,152)Odds ratio (95% CI)p-value	1.40 (1.13-1.73)*0.002	1.00 (ref)	0.86 (0.81-0.91)*<0.001	0.79 (0.74-0.85)*<0.001
Adjusted bleed (n=163,473)Odds ratio (95% CI)p-value	1.24 (1.00-1.54)0.049	1.00 (ref)	0.92 (0.86-0.97)*0.005	0.87 (0.81-0.93)*<0.001






Table 3: Adjusted odds of adverse outcome according to BMI group using imputed data according to diagnosis
Table 3: Adjusted odds of adverse outcome according to BMI group using imputed data according to diagnosis
Outcome	Stable anginaOdds ratio (95% CI)	UA / NSTEMIOdds ratio (95% CI)	STEMIOdds ratio (95% CI)
30 day mortalitynBMI <18.5 kg/m2BMI 18.5-24.9 kg/m2BMI 25-30 kg/m2BMI >30 kg/m2	163,4731.06 (0.39-2.91)1.00 (ref)0.76 (0.60-0.96)*0.90 (0.70-1.16)	130,4681.10 (0.76-1.59)1.00 (ref)0.81 (0.72-0.91)*0.84 (0.74-0.97)*	50,8541.32 (0.97-1.81)1.00 (ref)0.94 (0.84-1.05)0.95 (0.82-1.09)
1 year mortalitynBMI <18.5 kg/m2BMI 18.5-24.9 kg/m2BMI 25-30 kg/m2BMI >30 kg/m2	152,3301.74 (1.27-2.39)*1.00 (ref)0.66 (0.60-0.72)*0.71 (0.64-0.78)*	120,0571.99 (1.66-2.37)1.00 (ref)0.67 (0.63-0.71)*0.71 (0.66-0.77)*	45,6191.69 (1.35-2.11)*1.00 (ref)
0.79 (0.73-0.86)*0.78 (0.70-0.87)*
3 year mortalitynBMI <18.5 kg/m2BMI 18.5-24.9 kg/m2BMI 25-30 kg/m2BMI >30 kg/m2	117,5252.34 (1.87-2.92)*1.00 (ref)0.74 (0.70-0.79)*0.81 (0.76-0.87)*	86,9052.12 (1.79-2.52)*1.00 (ref)0.75 (0.71-0.80)*0.82 (0.77-0.87)*	25,9452.07 (1.60-2.67)*1.00 (ref)0.76 (0.69-0.83)*0.80 (0.71-0.90)*
5 year mortalitynBMI <18.5 kg/m2BMI 18.5-24.9 kg/m2BMI 25-30 kg/m2BMI >30 kg/m2	80,4852.46 (1.95-3.10)*1.00 (ref)0.78 (0.74-0.83)*0.88 (0.83-0.94)*	54,5982.60 (2.13-3.18)*1.00 (ref)0.77 (0.72-0.82)*0.87 (0.81-0.93)*	10,6932.12 (1.46-3.09)*1.00 (ref)0.82 (0.72-0.93)*0.87 (0.74-1.01)
MACE nBMI <18.5 kg/m2BMI 18.5-24.9 kg/m2BMI 25-30 kg/m2BMI >30 kg/m2	163,4730.94 (0.51-1.73)1.00 (ref)0.84 (0.75-0.95)*0.82 (0.72-0.93)*	130,4681.14 (0.79-1.65)1.00 (ref)0.97 (0.86-1.08)0.94 (0.79-1.65)	50,8540.92 (0.64-1.33)1.00 (ref)1.08 (0.96-1.20)1.12 (0.98-1.28)
Bleed nBMI <18.5 kg/m2BMI 18.5-24.9 kg/m2BMI 25-30 kg/m2BMI >30 kg/m2	163,4731.37 (0.89-2.12)1.00 (ref)0.90 (0.82-1.00)*0.86 (0.77-0.95)*	130,4681.32 (0.95-1.84)1.00 (ref)0.90 (0.81-0.99)*0.86 (0.77-0.96)*	50,8541.01 (0.65-1.57)1.00 (ref)0.99 (0.86-1.14)0.89 (0.75-1.05)




 Table 4: Inverse probability weighting by propensity scores analysis of adverse outcomes and BMI group using imputed data
Outcome	BMI <18.5 kg/m2vs BMI 18.5-24.9 kg/m2	BMI 25-30 kg/m2vs BMI 18.5-24.9 kg/m2	BMI >30 kg/m2vs BMI 18.5-24.9 kg/m2
30 day mortalityOdds ratio (95% CI)p-value	1.63 (0.97-2.75)0.065	0.63 (0.55-0.73)*<0.001	0.47 (0.39-0.56)*<0.001
1 year mortalityOdds ratio (95% CI)p-value	2.76 (2.11-3.61)*<0.001	0.56 (0.52-0.61)*<0.001	0.48 (0.43-0.53)*<0.001
3 year mortalityOdds ratio (95% CI)p-value	2.78 (2.17-3.55)*<0.001	0.60 (0.56-0.64)*<0.001	0.57 (0.52-0.62)*<0.001
5 year mortalityOdds ratio (95% CI)p-value	2.23 (1.66-2.98)*<0.001	0.65 (0.61-0.70)*<0.001	0.64 (0.58-0.69)*<0.001
MACEOdds ratio (95% CI)p-value	1.07 (0.63-1.82)0.80	0.76 (0.68-0.85)*<0.001	0.63 (0.55-0.72)*<0.001
Bleed Odds ratio (95% CI)p-value	1.20 (0.75-1.94)0.45	0.83 (0.75-0.91)*<0.001	0.75 (0.67-0.85)*<0.001













Smoker (current/ex)	317,183 (92%)	27,969 (8%)




Peripheral vascular disease	334,715 (97%)	10,437 (3%)
Previous MI	328,575 (95%)	16,577 (5%)
Previous stroke	334,715 (97%)	10,437 (3%)
Valvular heart disease	334,715 (97%)	10,437 (3%)
Renal disease	342,446 (99.2%)	2,706 (0.8%)
Previous PCI	337,406 (98%)	7,746 (2%)
Previous CABG	337,093 (98%)	8,059 (2%)
LV ejection fraction	170,601 (49%)	174,551 (51%)
Receipt of ventilation	314,528 (91%)	30,624 (9%)
Receipt of circulatory support	325,192 (94%)	19,960 (6%)
Cardiogenic shock	326,625 (95%)	18,527 (5%)
Left main 	333,040 (96%)	12,112 (4%)
Use of drug eluting stents	333,729 (97%)	11,423 (3%)
Access site	337,283 (98%)	7,869 (2%)







Supplementary Table 2:Risk of adverse outcomes among participants with BMI ≥30 kg/m2 by BMI group
Outcome	BMI 18.5-24.9 kg/m2	BMI 30.0-34.9 kg/m2	BMI 35.0-39.9 kg/m2	BMI ≥40 kg/m2
30 day mortality (n=195,577)Unadjusted OR (95% CI) p-valueAdjusted value OR (95% CI)p-value	1.00 (ref)1.00 (ref)	0.46 (0.43-0.50)*<0.0010.82 (0.74-0.90)*<0.001	0.51 (0.45-0.59)*<0.0010.99 (0.85-1.15)0.89	0.69 (0.58-0.82)*<0.0011.42 (1.16-1.73)*0.001
1 year mortality (n=180,113)Unadjusted ORp-valueAdjusted value ORp-value	1.00 (ref)1.00 (ref)	0.46 (0.43-0.48)*<0.0011.07 (0.95-1.20)*0.29	0.52 (0.48-0.56)*<0.0010.67 (0.63-0.71)*<0.001	0.63 (0.56-0.70)*<0.0010.81 (0.74-0.89)*<0.001
3 year mortality (n=130,190)Unadjusted OR p-valueAdjusted value ORp-value	1.00 (ref)1.00 (ref)	0.56 (0.53-0.58)*<0.0011.20 (1.09-1.32)*<0.001	0.60 (0.57-0.65)*<0.0010.75 (0.72-0.79)*<0.001	0.75 (0.68-0.82)*<0.0010.88 (0.81-0.94)*0.001
5 year mortality (n=82,292)Unadjusted ORp-valueAdjusted value OR p-value	1.00 (ref)1.00 (ref)	0.63 (0.60-0.66)*<0.0011.23 (1.11-1.37)<0.001	0.67 (0.63-0.72)*<0.0010.82 (0.78-0.86)*<0.001	0.80 (0.73-0.87)*<0.0010.94 (0.87-1.02)0.13
MACE (n=195,577)Unadjusted ORp-valueAdjusted value ORp-value	1.00 (ref)1.00 (ref)	0.67 (0.62-0.72)*<0.0011.17 (0.99-1.38)0.061	0.66 (0.59-0.74)*<0.0010.93 (0.85-1.00)0.059	0.79 (0.68-0.92)0.0030.95 (0.83-1.07)0.38
Bleed (n=195,477)Unadjusted ORp-valueAdjusted value ORp-value	1.00 (ref)1.00 (ref)	0.77 (0.72-0.83)*<0.0010.77 (0.65-0.92)*0.003	0.89 (0.80-0.99)*0.0270.84 (0.78-0.91)*<0.001	0.74 (0.63-0.87)*<0.0010.97 (0.87-1.08)0.53






Supplementary Table 3: Crude and adjusted odds of adverse outcome according to BMI group using imputed data for years before or 2009
Outcome/adjustment	BMI <18.5 kg/m2	BMI 18.5-24.9 kg/m2	BMI 25-30 kg/m2	BMI >30 kg/m2
Unadjusted 30 day mortality (n=164,527)Odds ratio (95% CI)p-value	1.50 (1.03-2.17)*0.032	1.00 (ref)	0.68 (0.61-0.75)*<0.001	0.58 (0.52-0.66)*<0.001
Adjusted 30 day mortality (n=164,527)Odds ratio (95% CI)p-value	1.16 (0.78-1.73)0.46	1.00 (ref)	0.94 (0.84-1.06)0.33	1.03 (0.90-1.19)0.67
Unadjusted 1 year mortality (n=161,608)Odds ratio (95% CI)p-value	2.39 (2.00-2.85)*<0.001	1.00 (ref)	0.57 (0.54-0.61)*<0.001	0.52 (0.49-0.56)*<0.001
Adjusted 1 year mortality (n=164,527)Odds ratio (95% CI)p-value	1.98 (1.62-2.40)*<0.001	1.00 (ref)	0.71 (0.66-0.76)*<0.001	0.75 (0.70-0.81)*<0.001
Unadjusted 3 year mortality (n=161,446)Odds ratio (95% CI)p-value	2.62 (2.29-2.99)*<0.001	1.00 (ref)	0.62 (0.60-0.65)*<0.001	0.61 (0.58-0.64)*<0.001
Adjusted 3 year mortality (n=161,446)Odds ratio (95% CI)p-value	2.33 (2.01-2.70)*<0.001	1.00 (ref)	0.74 (0.71-0.78)*<0.001	0.82 (0.78-0.87)*<0.001
Unadjusted MACE (n=164,527)Odds ratio (95% CI)p-value	1.17 (0.82-1.66)0.39	1.00 (ref)	0.79 (0.72-0.86)*<0.001	0.71 (0.64-0.78)*<0.001
Adjusted MACE (n=164,527)Odds ratio (95% CI)p-value	1.04 (0.72-1.50)0.85	1.00 (ref)	0.92 (0.84-1.01)0.08	0.92 (0.82-1.02)0.10
Unadjusted bleed (n=164,527)Odds ratio (95% CI)p-value	1.43 (1.08-1.90)0.014	1.00 (ref)	0.83 (0.77-0.90)*<0.001	0.77 (0.71-0.84)*<0.001
Adjusted bleed (n=164,527)Odds ratio (95% CI)p-value	1.26 (0.94-1.68)0.12	1.00 (ref)	0.88 (0.81-0.85)*0.001	0.82 (0.75-0.89)*<0.001






Supplementary Table 4: Crude and adjusted odds of adverse outcome according to BMI group using imputed data for years after 2009
Outcome/adjustment	BMI <18.5 kg/m2	BMI 18.5-24.9 kg/m2	BMI 25-30 kg/m2	BMI >30 kg/m2
Unadjusted 30 day mortality (n=180,625)Odds ratio (95% CI)p-value	1.72 (1.35-2.18)*<0.001	1.00 (ref)	0.57 (0.53-0.62)*<0.001	0.45 (0.40-0.49)*<0.001
Adjusted 30 day mortality (n=180,625)Odds ratio (95% CI)p-value	1.23 (0.93-1.62)0.15	1.00 (ref)	0.81 (0.73-0.89)*<0.001	0.82 (0.73-0.92)*0.001
Unadjusted 1 year mortality (n=156,724)Odds ratio (95% CI)p-value	2.25 (1.95-2.61)*<0.001	1.00 (ref)	0.53 (0.50-0.56)*<0.001	0.46 (0.43-0.48)*<0.001
Adjusted 1 year mortality (n=156,724)Odds ratio (95% CI)p-value	1.74 (1.47-2.06)*<0.001	1.00 (ref)	0.69 (0.65-0.73)*<0.001	0.7 2 (0.67-0.77)*<0.001
Unadjusted 3 year mortality (n=69,193)Odds ratio (95% CI)p-value	2.42 (2.04-2.86)*<0.001	1.00 (ref)	0.60 (0.56-0.63)*<0.001	0.54 (0.51-0.58)*<0.001
Adjusted 3 year mortality (n=69,193)Odds ratio (95% CI)p-value	1.91 (1.57-2.32)*<0.001	1.00 (ref)	0.76 (0.71-0.81)*<0.001	0.81 (0.75-0.87)*<0.001
Unadjusted MACE (n=180,625)Odds ratio (95% CI)p-value	1.28 (0.97-1.70)0.09	1.00 (ref)	0.77 (0.71-0.83)*<0.001	0.65 (0.60-0.71)*<0.001
Adjusted MACE (n=180,625)Odds ratio (95% CI)p-value	0.99 (0.73-1.35)0.95	1.00 (ref)	0.99 (0.91-1.08)0.90	0.98 (0.89-1.09)0.75
Unadjusted bleed (n=180,625)Odds ratio (95% CI)p-value	1.42 (1.03-1.96)*0.03	1.00 (ref)	0.89 (0.82-0.98)*0.016	0.83 (0.75-0.92)*<0.001
Adjusted bleed (n=180,625)Odds ratio (95% CI)p-value	1.20 (0.87-1.67)0.27	1.00 (ref)	0.98 (0.89-1.07)0.62	0.94 (0.85-1.05)0.27





Supplementary Table 5: Crude and adjusted odds of adverse outcome according to BMI group using imputed data for patients without diabetes
Outcome/adjustment	BMI <18.5 kg/m2	BMI 18.5-24.9 kg/m2	BMI 25-30 kg/m2	BMI >30 kg/m2
Unadjusted 30 day mortality (n=277,867)Odds ratio (95% CI)p-value	1.85 (1.49-2.29)*<0.001	1.00 (ref)	0.58 (0.54-0.62)*<0.001	0.46 (0.41-0.49)*<0.01
Adjusted 30 day mortality (n=277,867)Odds ratio (95% CI)p-value	1.28 (1.00-1.63)*0.049	1.00 (ref)	0.85 (0.78-0.93)*<0.001	0.91 (0.82-1.01)0.09
Unadjusted 1 year mortality (n=257,131)Odds ratio (95% CI)p-value	2.51 (2.22-2.84)*<0.001	1.00 (ref)	0.52 (0.50-0.55)*<0.001	0.41 (0.39-0.44)*<0.001
Adjusted 1 year mortality (n=257,131)Odds ratio (95% CI)p-value	1.89 (1.65-2.17)*<0.001	1.00 (ref)	0.71 (0.67-0.74)*<0.001	0.73 (0.69-0.78)*<0.001
Unadjusted 3 year mortality (n=187,760)Odds ratio (95% CI)p-value	2.68 (0.240-3.00)*<0.001	1.00 (ref)	0.58 (0.56-0.61)*<0.001	0.49 (0.46-0.51)*<0.001
Adjusted 3 year mortality (n=187,760)Odds ratio (95% CI)p-value	2.21 (1.95-2.51)*<0.001	1.00 (ref)	0.75 (0.72-0.78)*<0.001	0.78 (0.74-0.82)*<0.001
Unadjusted 5 year mortality (n=119,300)Odds ratio (95% CI)p-value	2.81 (2.48-3.20)*<0.001	1.00 (ref)	0.63 (0.61-0.66)*<0.001	0.55 (0.53-0.58)*<0.001
Adjusted 5 year mortality (n=119,300)Odds ratio (95% CI)p-value	2.56 (2.21-2.96)*<0.001	1.00 (ref)	0.78 (0.75-0.82)*<0.001	0.85 (0.80-0.89)*<0.001
Unadjusted MACE (n=277,867)Odds ratio (95% CI)p-value	1.36 (1.08-1.72)*0.009	1.00 (ref)	0.79 (0.74-0.84)*<0.001	0.68 (0.63-0.73)*<0.001
Adjusted MACE (n=277,867)Odds ratio (95% CI)p-value	1.09 (0.85-1.40)0.48	1.00 (ref)	0.98 (0.91-1.05)0.57	0.97 (0.90-1.06)0.51
Unadjusted bleed (n=277,867)Odds ratio (95% CI)p-value	1.40 (1.12-1.76)*0.003	1.00 (ref)	0.87 (0.82-0.93)*<0.001	0.81 (0.75-0.87)*<0.001
Adjusted bleed (n=277,867)Odds ratio (95% CI)p-value	1.27 (1.01-1.59)*0.043	1.00 (ref)	0.93 (0.87-0.99)*0.022	0.87 (0.80-0.94)*<0.001





Supplementary Table 6: Crude and adjusted odds of adverse outcome according to BMI group using imputed data for patients with diabetes
Outcome/adjustment	BMI <18.5 kg/m2	BMI 18.5-24.9 kg/m2	BMI 25-30 kg/m2	BMI >30 kg/m2
Unadjusted 30 day mortality (n=67,119)Odds ratio (95% CI)p-value	1.06 (0.55-2.06)<0.001	1.00 (ref)	0.62 (0.54-0.71)*<0.001	0.43 (0.38-0.50)*<0.001
Adjusted 30 day mortality (n=67,119)Odds ratio (95% CI)p-value	0.88 (0.43-1.80)0.72	1.00 (ref)	0.87 (0.75-1.02)0.10	0.85 (0.72-1.01)0.06
Unadjusted 1 year mortality (n=61,044)Odds ratio (95% CI)p-value	1.83 (1.33-2.52)*<0.001	1.00 (ref)	0.54 (0.50-0.59)*<0.001	0.44 (0.40-0.47)*<0.001
Adjusted 1 year mortality (n=61,044)Odds ratio (95% CI)p-value	1.56 (1.08-2.25)*0.02	1.00 (ref)	0.68 (0.62-0.75)*<0.001	0.71 (0.64-0.78)*<0.001
Unadjusted 3 year mortality (n=42,765)Odds ratio (95% CI)p-value	2.35 (1.73-3.19)*<0.001	1.00 (ref)	0.63 (0.58-0.67)*<0.001	0.57 (0.53-0.61)*<0.001
Adjusted 3 year mortality (n=42,765)Odds ratio (95% CI)p-value	1.96 (1.39-2.76)*<0.001	1.00 (ref)	0.77 (0.71-0.84)*<0.001	0.89 (0.81-0.96)*0.005
Unadjusted 5 year mortality (n=26,574)Odds ratio (95% CI)p-value	2.38 (1.62-3.51)*<0.001	1.00 (ref)	0.66 (0.61-0.72)*<0.001	0.63 (0.58-0.69)*<0.001
Adjusted 5 year mortality (n=26,574)Odds ratio (95% CI)p-value	2.10 (1.35-3.25)*0.001	1.00 (ref)	0.79 (0.72-0.87)*<0.001	0.94 (0.86-1.04)0.22
Unadjusted MACE (n=67,119)Odds ratio (95% CI)p-value	0.63 (0.25-1.56)0.32	1.00 (ref)	0.69 (0.60-0.79)*<0.001	0.55 (0.48-0.63)*<0.001
Adjusted MACE (n=67,119)Odds ratio (95% CI)p-value	0.56 (0.22-1.44)0.23	1.00 (ref)	0.87 (0.75-1.01)0.07	0.88 (0.75-1.02)0.09
Unadjusted bleed (n=67,119)Odds ratio (95% CI)p-value	1.32 (0.65-2.66)0.44	1.00 (ref)	0.76 (0.64-0.90)*0.002	0.75 (0.64-0.88)*<0.001
Adjusted bleed (n=67,119)Odds ratio (95% CI)p-value	1.15 (0.57-2.35)0.69	1.00 (ref)	0.83 (0.70-0.99)*0.04	0.84 (0.71-0.99)*0.03
Adjusted for age, gender, year, race, smoker, family history of CAD, hypertension, hypercholesterolaemia, peripheral vascular disease, previous MI, previous stroke, valvular heart disease, renal disease, previous PCI, previous CABG, lvef, receipt of ventilation, receipt of circulatory support, cardiogenic shock, left main, use of drug eluting stents, radial access, glycoprotein IIb/IIIa inhibitor use and diagnosis.
*=significant




